- For Print
- July 19, 2021
Eisai Co., Ltd. continues to stand behind the U.S. Food and Drug Administration (FDA) approval of ADUHELM™ (aducanumab-avwa) and the data from clinical studies described in the label. Eisai has been engaged in providing medical professionals in clinical practices with information to help educate about the medication’s label. Currently, we are focused on promoting ADUHELM at medical institutions and improving drug access for patients, including increasing the number of infusion centers capable of administering ADUHELM. Eisai remains committed to supporting access to ADUHELM for all appropriate patients.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.